

Immune thrombocytopenia market will see minimal growth to \$985 million by 2025

Écrit par GlobalData
Mardi, 21 Mars 2017 22:30 -

GlobalData»

The immune thrombocytopenia (ITP) market across the seven major countries of the US, France, Germany,

The company's [latest report](#) states that the ITP space will see reasonable growth at the beginning

From 2023, however, market value will start declining due to the patent expiration and subsequent generic

Fenix Leung, DPhil, Healthcare Analyst for GlobalData, explains: "Companies are looking into drugs with

GlobalData has determined that the ITP market has a weak pipeline. Since the approval of Nplate and

Avatrombopag has encountered difficulties in clinical trial participant recruitment, and GlobalData believes

Leung concludes: "Despite the harsh market environment, GlobalData sees ample opportunity for pharma

"Ultimately, the ITP market is looking for curative therapies that offer long-term remission for patients, and